Bexorg offers the BrainEx platform, a whole‑human brain perfusion system that keeps donated post‑mortem brains metabolically active for days, allowing precise delivery of drugs, biologics, or gene therapies across an intact blood‑brain barrier. Integrated AI analyzes longitudinal omics data to produce predictive models of disease and drug response, giving pharmaceutical and biotech companies translationally relevant preclinical data to de‑risk CNS programs and accelerate therapeutic discovery.
Funding
$23M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
3OFounders
Product
Problem
Current central nervous system (CNS) drug development relies on simplified models such as cell cultures, organoids, or animal brains, which fail to capture the complexity of the human brain. This mismatch leads to a >95% failure rate of CNS clinical trials, delaying effective therapies for patients with neurological diseases.
Solution
Bexorg has created the BrainEx platform, a whole‑human brain perfusion system that maintains molecular activity in donated, post‑mortem human brains for days. By connecting the brain’s vascular network to an artificial perfusate, the platform delivers drugs, biologics, or gene therapies while preserving the blood‑brain barrier and enabling real‑time measurement of exposure, target engagement, and functional pharmacology. Integrated AI (XO Digital) analyzes longitudinal omics data from tissue and fluid samples to generate causal, predictive models of disease and drug response. This approach provides translationally relevant data that can de‑risk CNS programs before entering human trials, accelerating discovery and improving clinical success rates.
Target Audience
Primary customers are pharmaceutical and biotech companies developing CNS therapeutics, as well as academic and contract research organizations seeking human‑relevant data for target validation and preclinical testing.
Features
- Whole‑human brain perfusion system that sustains cellular function in intact post‑mortem brains for extended periods
- Vascular connection and artificial perfusate enable precise delivery of therapeutics across an intact blood‑brain barrier
- Real‑time monitoring of molecular exposure, target engagement, and functional biomarkers
- Integrated AI platform that transforms multi‑omics time‑course data into predictive, causal models for drug discovery
- Capability to test small molecules, biologics, and gene therapies directly in human brain tissue
- Longitudinal sampling of tissue and biofluids to map dynamic molecular responses across disease states